Earnings call: Innate Pharma reports progress in drug development
Innate Pharma (Euronext Paris: IPH) has reported encouraging advancements in its proprietary drug candidates, particularly lacutamab for T-cell lymphoma, during its First-Half 2024 Earnings Call. The company, which is celebrating its 25th…